We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-7.67 | -4.58% | 159.6218 | 167.46 | 157.65 | 167.26 | 10,721,784 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * SALEKI-GERHARDT AZITA | 2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ ABBV ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP, OPERATIONS |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock, $0.01 par value | 2/16/2023 | A | 48127 (1) | A | $0 | 206039 | D | |||
Common Stock, $0.01 par value | 2/16/2023 | A | 11229 (2) | A | $0 | 217268 | D | |||
Common Stock, $0.01 par value | 2/16/2023 | A | 8560 (3) | A | $0 | 225828 | D | |||
Common Stock, $0.01 par value | 2/16/2023 | A | 7380 (4) | A | $0 | 233208 | D | |||
Common Stock, $0.01 par value | 2/17/2023 | M | 25000 | A | $51.42 | 258208 | D | |||
Common Stock, $0.01 par value | 2/17/2023 | S | 14246 | D | $149.13 (5) | 243962 | D | |||
Common Stock, $0.01 par value | 2/17/2023 | S | 10754 | D | $150.05 (6) | 233208 | D | |||
Common Stock, $0.01 par value | 2322 (7) | I | Profit sharing trust | |||||||
Common Stock, $0.01 par value | 3873 (8) | I | By spouse |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Option (Right to Buy) (9) | $149.62 | 2/16/2023 | A | 22957 | 2/16/2024 | 2/15/2033 | Common Stock | 22957 | $0 | 22957 | D | ||||
Option (Right to Buy) (10) | $51.42 | 2/17/2023 | M | 25000 | 2/20/2015 | 2/19/2024 | Common Stock | 25000 | $51.42 | 0 | D |
Remarks: The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c). |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
SALEKI-GERHARDT AZITA 1 N. WAUKEGAN ROAD NORTH CHICAGO, IL 60064 | EVP, OPERATIONS |
Signatures | ||
Steven L. Scrogham, attorney-in-fact for Azita Saleki-Gerhardt | 2/21/2023 | |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions